If you or a loved one is taking Tysabri, you may be concerned about the risk of PML—a rare but serious brain infection. Decades of pharmacovigilance have established that risk stratification and regular monitoring are essential for early detection. This page explains the PML risk signals within the context of the RI (Risk Identification) framework, helping you understand the monitoring guidelines and what they mean for your care.
Tysabri (natalizumab) is a monoclonal antibody used primarily in the treatment of multiple sclerosis and Crohn's disease. Its association with progressive multifocal leukoencephalopathy (PML) is a well-documented and serious safety concern. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV), which typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, emphasizing that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic pathway linking Tysabri to PML involves the drug's action on the immune system. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing the JC virus to reactivate and cause PML. The clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive impairment, and visual disturbances. Diagnosis is typically confirmed by brain MRI and detection of JCV DNA in cerebrospinal fluid. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 patients with Crohn's disease evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight the risk even with relatively short exposure. The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events, its severity warrants heightened vigilance.
The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and the TOUCH Prescribing Program, a restricted distribution program that ensures patients are monitored and educated about PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, causation-related considerations for affected patients remain complex. The timeline between Tysabri exposure and documented harm can vary, with PML occurring after as few as eight doses or after several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability complicates risk assessment and underscores the need for ongoing monitoring. For patients who develop PML, the prognosis is poor, with most cases leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk-benefit analysis for Tysabri must carefully weigh the potential for improved disease control against the risk of this devastating adverse event. The FDA's boxed warning and the TOUCH program aim to mitigate this risk, but they cannot eliminate it entirely.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA has issued a boxed warning for Tysabri, emphasizing that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The warning is part of the TOUCH Prescribing Program, which requires monitoring and education for patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri binds to alpha-4 integrins on immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation but also impairs immune surveillance, allowing the JC virus to reactivate and cause PML. The mechanism is well-documented in the drug's prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.